Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael B Boffa

Showing results (11-20 of 73) with videos related to

Pageof 8
Sort By:
Current Opinion in Lipidology|October 3, 2019
Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?Michael B Boffa, Marlys L Koschinsky
Atherosclerosis|May 23, 2022
Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiologyMarlys L Koschinsky, Michael B Boffa
The Biochemical Journal|September 20, 2024
Lipoprotein(a) and cardiovascular diseaseMichael B Boffa, Marlys L Koschinsky
Clinical Biochemistry|March 3, 2007
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological rolesMichael B Boffa, Marlys L Koschinsky
Research and Practice in Thrombosis and Haemostasis|July 10, 2024
Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potentialTanya T Marar, Michael B Boffa
Journal of Thrombosis and Thrombolysis|June 13, 2023
Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzymeJustin J W Garabon, Michael B Boffa
Plos One|January 18, 2013
Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation systemLei Liu, Michael B Boffa, Marlys L Koschinsky
Critical Reviews in Clinical Laboratory Sciences|December 22, 2017
Lipoprotein(a) in clinical practice: New perspectives from basic and translational scienceCorey A Scipione, Marlys L Koschinsky, Michael B Boffa
Clinical Biochemistry|April 17, 2004
Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal modelsMichael B Boffa, Santica M Marcovina, Marlys L Koschinsky
Current Opinion in Lipidology|August 1, 2025
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targetsJulia M Assini, Michael B Boffa, Marlys L Koschinsky
Pageof 8

Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
Current Opinion in Lipidology|October 3, 2019
Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?Michael B Boffa, Marlys L Koschinsky
Atherosclerosis|May 23, 2022
Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiologyMarlys L Koschinsky, Michael B Boffa
The Biochemical Journal|September 20, 2024
Lipoprotein(a) and cardiovascular diseaseMichael B Boffa, Marlys L Koschinsky
Clinical Biochemistry|March 3, 2007
Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological rolesMichael B Boffa, Marlys L Koschinsky
Research and Practice in Thrombosis and Haemostasis|July 10, 2024
Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potentialTanya T Marar, Michael B Boffa
Journal of Thrombosis and Thrombolysis|June 13, 2023
Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzymeJustin J W Garabon, Michael B Boffa
Plos One|January 18, 2013
Apolipoprotein(a) inhibits in vitro tube formation in endothelial cells: identification of roles for Kringle V and the plasminogen activation systemLei Liu, Michael B Boffa, Marlys L Koschinsky
Critical Reviews in Clinical Laboratory Sciences|December 22, 2017
Lipoprotein(a) in clinical practice: New perspectives from basic and translational scienceCorey A Scipione, Marlys L Koschinsky, Michael B Boffa
Clinical Biochemistry|April 17, 2004
Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal modelsMichael B Boffa, Santica M Marcovina, Marlys L Koschinsky
Current Opinion in Lipidology|August 1, 2025
The complex pro-atherosclerotic role of lipoprotein(a): a multiplicity of cellular targetsJulia M Assini, Michael B Boffa, Marlys L Koschinsky
Pageof 8